Immucell sees FY25 revenue $111M-$113M, consensus $107.93M

The company said, “The Company is raising its full year 2025 revenue guidance range to $111.0 million to $113.0 million, representing 10% year-over-year growth at the midpoint. The Company is also raising its Adjusted EBITDA margin guidance to 21% to 23% for the full year 2025. The Company also expects ARR to increase from $95.6 million at the beginning of 2025 to approximately $110.0 million at the start of 2026.”